Skip to main content
Equibles
IDYA logo

IDYA · IDEAYA Biosciences, Inc.

Track IDYA — free

Use IDYA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IDYA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$37.59 +0.14 (+0.37%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$3.63B
Shares
96.49M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$37.59 Open$37.74 Day$37.24–38.27 52W close$24.44–42.48 Avg vol 30d691K Short int10.1M · 10.5% float · 12.2d Short vol78% Last earningsNov 4, 2024 DataJan 2020–Sep 2026 Filing10-Q · Aug 4

Up next

Latest filing: 10-Q
filed Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$175.02M
Trailing 12 months
Revenue growth YoY
+3,024.4%
Year over year
Operating margin
-72.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$828.96M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.1%
Year over year · more shares
Price change (1Y)
+51.6%
Trailing year
Short interest
10.5%
Latest settlement · 12.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +11%
above
Price vs 50-day avg −0%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 73%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +2%
trailing
6-month return +15%
trailing
YTD return +9%
this year
Relative strength −3%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $38 › 200d $34 — 50d above 200d
Institutional flow Accumulating
+12% holders QoQ · +66 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.47% of float · ▼ -2.8% MoM · 12.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
287 holders — near 3-yr high, broad support
Squeeze score 74
high risk · 0–100
Fundamentals
Strong
Revenue growth +3024%
Y/Y
EPS growth +62%
Y/Y
Free cash flow $-73.5M
Quant / Vol
risk profile
High
Volatility 46%
annualized · 1-yr
Max drawdown −27%
past year
ATR 3.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+11% Bullish
Price vs 50-day avg
−0% Neutral
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
73% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $38 › 200d $34 — 50d above 200d
Institutional flow Accumulating
+12% holders QoQ · +66 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.47% of float · ▼ -2.8% MoM · 12.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
287 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $24 Now $38 · 73% Range high $42
vs 200-day avg +11% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IDYA
IDEAYA Biosciences, Inc.
this stock
$3.63B +8.7% +3024.4% — 10.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
287
% held
106.7%
Net QoQ
+5.9M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
259
View
Short & Settlement
Short Interest Falling
Shares short
10.1M
Days to cover
12.2d
Change
-294.3K sh
View
Short Volume
Short vol %
78%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
3
Value
$110
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$218.7M
Net income (FY)
$-113.7M
EPS diluted
$-1.28
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 8, 2026
This year
19
View
Proposed Sales
Value
$3.0M
Shares
75.0K
Filed
Aug 26, 2024
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 14, 2026
Last call
Sep 10, 2026
View
Investor Relations
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
IDYA -6.0% +2.5% +14.8% -6.3% +8.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -4.8% +4.2% -3.1% -5.9% -3.3%
Key facts CIK 1676725 CUSIP 45166A102 13F (30d) 94 filings 93 filers Visit website Investor relations